目的:评估0.23%聚维酮碘(PVP-I)鼻腔冲洗液和漱口水对2019年冠状病毒病(COVID-19)病毒的可检测性和鼻咽拭子中的循环阈值(Ct)值的有效性。
方法:这是一个开放标签,prospective,随机化,安慰剂对照临床试验。
方法:本研究在沙特国王大学医学城进行,利雅得,沙特阿拉伯,从2021年8月到2022年7月。
方法:被诊断为SARS-CoV-2的参与者被随机分配到三组中的一组,参与者接受0.23%的PVP-I,0.9%生理盐水(NS)鼻腔冲洗和漱口水,或不干预(对照组)。在第一次拭子后4、8、12和18天取鼻咽拭子以测量病毒和Ct的可检测性。
结果:共有19名参与者参与了这项研究。PVP-I的平均病毒生存期为9.8、12和12.6天,NS,和对照组,分别,差异有统计学意义(p=0.046)。招募时的Ct平均值为23±3.4、23.5±6.3和26.3±5.9,PVP-I在4天后为25.2±3.5、15±11.7和26.9±6.4。NS,和对照组,分别。
结论:以0.23%的浓度连续使用时,PVP-I在通过减少传染性和病毒载量来减少大流行负担方面显示出有希望的结果。然而,在最近接种疫苗和轻度COVID-19患者中,使用PVP-I并未导致生活质量参数的显著不同变化.
OBJECTIVE: To assess the efficacy of 0.23% povidone-iodine (PVP-I) nasal rinses and mouth washes on detectability of the coronavirus disease 2019 (COVID-19) virus and cycle threshold (Ct) values in nasopharyngeal swabs.
METHODS: This was an open-label, prospective, randomized, placebo-controlled clinical trial.
METHODS: The study was conducted in King Saud University Medical City, Riyadh, Saudi Arabia, from August 2021 to July 2022.
METHODS: Participants diagnosed with SARS-CoV-2 were randomly assigned to one of three groups, with participants receiving either 0.23% PVP-I, 0.9% normal saline (NS) nasal rinses and mouth washes, or no intervention (control group). Nasopharyngeal swabs were taken 4, 8, 12, and 18 days after the first swab to measure the detectability of the virus and the Ct.
RESULTS: A total of 19 participants were involved in this study. The mean viral survival was 9.8, 12, and 12.6 days for the PVP-I, NS, and control groups, respectively, with a statistically significant difference (p = 0.046). The Ct mean values were 23 ± 3.4, 23.5 ± 6.3, and 26.3 ± 5.9 at the time of recruitment and 25.2 ± 3.5, 15 ± 11.7, and 26.9 ± 6.4 after 4 days for the PVP-I, NS, and control groups, respectively.
CONCLUSIONS: When used continuously at a concentration of 0.23%, PVP-I showed promising results in terms of decreasing the pandemic burden by reducing the period of infectiousness and viral load. However, the use of PVP-I did not result in significantly different changes in the quality-of-life parameters in recently vaccinated and mild COVID-19 patients.